SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001193125-12-150122
Filing Date
2012-04-04
Accepted
2012-04-04 16:44:09
Documents
11
Period of Report
2011-12-31

Document Format Files

Seq Description Document Type Size
1 FORM 10-K d327746d10k.htm 10-K 826999
2 CONSENT OF REZNICK GROUP, P.C d327746dex231.htm EX-23.1 1688
3 SECTION 302 CEO CERTIFICATION d327746dex311.htm EX-31.1 9373
4 SECTION 302 CFO CERTIFICATION d327746dex312.htm EX-31.2 9218
5 SECTION 906 CEO AND CFO CERTIFICATION d327746dex321.htm EX-32.1 4264
  Complete submission text file 0001193125-12-150122.txt   3019215

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT rgn-20111231.xml EX-101.INS 476304
7 XBRL TAXONOMY EXTENSION SCHEMA rgn-20111231.xsd EX-101.SCH 11950
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE rgn-20111231_cal.xml EX-101.CAL 19296
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rgn-20111231_def.xml EX-101.DEF 7575
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgn-20111231_lab.xml EX-101.LAB 94192
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgn-20111231_pre.xml EX-101.PRE 63640
Mailing Address 3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814
Business Address 3 BETHESDA METRO CENTER SUITE 700 BETHESDA MD 20814 3019611992
REGENERX BIOPHARMACEUTICALS INC (Filer) CIK: 0000707511 (see all company filings)

IRS No.: 521253406 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-15070 | Film No.: 12742424
SIC: 2834 Pharmaceutical Preparations